Retrospective analysis of Tripterygium wilfordii polyglycoside combined with angiotensin receptor blockers for the treatment of primary membranous nephropathy with sub-nephrotic proteinuria

References

• Hanko JB., Mullan RN., O’Rourke DM., McNamee PT., The changing pattern of adult primary glomerular disease. Nephrol Dial Transplant. 2009;24(10):3050–3054.
   PubMed Web of Science ®Google Scholar
• Floege J, Barbour SJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019;95(2):268–80.
   PubMedGoogle Scholar
• Hladunewich MA, Troyanov S, Calafati J, Cattran DC, Metropolitan Toronto Glomerulonephritis R. The natural history of the non-nephrotic membranous nephropathy patient. CJASN. 2009;4(9):1417–22.
   PubMed Web of Science ®Google Scholar
• Hoxha E, Harendza S, Pinnschmidt H, Panzer U, Stahl RA. PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system. PLoS One. 2014;9(10):e110681.
   PubMed Web of Science ®Google Scholar
• Yuan K, Li X, Lu Q, et al. Application and mechanisms of triptolide in the treatment of inflammatory diseases-a review. Front Pharmacol. 2019;10:1469.
   PubMed Web of Science ®Google Scholar
• Chen YZ, Gao Q, Zhao XZ, et al. Meta-analysis of Tripterygium wilfordii Hook F in the immunosuppressive treatment of IgA nephropathy. Intern Med. 2010;49(19):2049–2055.
   PubMed Web of Science ®Google Scholar
• Mao SJ, Huang XM. Tripterygium wilfordii Hook F is efficacious in the treatment of Henoch-Schonlein purpura nephritis in children. World J Pediatr. 2016;12(3):375–376.
   PubMedGoogle Scholar
• Liu S, Li X, Li H, et al. Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study. BMC Nephrol, 12015;16:200.
   PubMedGoogle Scholar
• Shang SL, Cai GY, Duan SW, et al. Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy. BMC Nephrol. 2018;19(1):182.
   PubMedGoogle Scholar
• Ruggenenti P, Fervenza FC, Remuzzi G. Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol. 2017;13(9):563–579.
   PubMed Web of Science ®Google Scholar
• Jones DB. Nephrotic glomerulonephritis. Am J Pathol. 1957;33(2):313–329.
   PubMed Web of Science ®Google Scholar
• Trujillo H, Alonso M, Praga M. New ways of understanding membranous nephropathy. Nephron. 2020;144(6):261–71.
   PubMed Web of Science ®Google Scholar
• Keri KC, Blumenthal S, Kulkarni V, Beck L, Chongkrairatanakul T. Primary membranous nephropathy: comprehensive review and historical perspective. Postgrad Med J. 2019;95(1119):23–31.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Patrizia P, Del Vecchio L, Locatelli F. The evolution of the therapeutic approach to membranous nephropathy. Nephrol Dial Transplant. 2020;3(24):1–6.
   Google Scholar
• Pei WY, Yang CH, Zhang XL. Effects and mechanism of Tripterygium wilfordii on chronic glomerulo nephritis. Genet Mol Res. 2016;15(1):1–7.
   Web of Science ®Google Scholar
• Chen MF, Zhang QY, Yao J, et al. Treatment of chronic nephritis with tripterygium hypoglaucum. A clinical and experimental study. J Trad Chin Med. 1983;3(3):219–222.
   PubMedGoogle Scholar
• Wang Z, Yu C, Zhou LN, Chen X. Effects of tripterygium wilfordii induction therapy to IgA nephropathy patients with heavy proteinuria. Biol Pharm Bull. 2017;40(11):1833–1838.
   PubMed Web of Science ®Google Scholar
• Xu G, Tu W, Jiang D, Xu C. Tripterygium wilfordii Hook F treatment for idiopathic refractory nephrotic syndrome in adults: a meta-analysis. Nephron Clin Pract. 2009;111(4):c223–c228.
   PubMedGoogle Scholar
• Wu X, Xu J, Luo X. Effects of Tripterygium hypoglaucum on serum IL-1, IL-6, and TNF-alpha in chronic nephritis rats. Zhongguo Zhong Yao za Zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica 2010;35(24):3354–3356.
   PubMedGoogle Scholar
• Chen ZH, Qin WS, Zeng CH, et al. Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro. Kidney Int. 2010;77(11):974–88.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Hong Y, Huang H. Triptolide attenuates inflammatory response in membranous glomerulo-nephritis rat via downregulation of NF-kappaB signaling pathway. Kidney Blood Press Res. 2016;41(6):901–910.
   PubMed Web of Science ®Google Scholar
• Ronco P, Debiec H. Anti-phospholipase A2 receptor antibodies and the pathogenesis of membranous nephropathy. Nephron Clin Pract. 2014;128(3-4):232–237.
   PubMedGoogle Scholar
• Lee S. Anti-phospholipase A2 receptor antibodies in membranous nephropathy. Kidney Res Clin Pract. 2018;37(3):181–182.
   PubMed Web of Science ®Google Scholar
• Yin P, Wang J, Liang W, et al. Outcomes of primary membranous nephropathy based on serum anti-phospholipase A2 receptor antibodies and glomerular phospholipase A2 receptor antigen status: a retrospective cohort study. Renal Failure. 2020;42(1):675–683.
   PubMed Web of Science ®Google Scholar
• Podesta MA, Gennarini A, Portalupi V, et al. Accelerating the depletion of circulating anti-phospholipase A2 receptor antibodies in patients with severe membranous nephropathy: preliminary findings with double filtration plasmapheresis and ofatumumab. Nephron. 2020;144(1):30–35.
   PubMed Web of Science ®Google Scholar
• Tao X, Lipsky PE. The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum Dis Clin North Am. 2000;26(1):29–50, viii.
   PubMed Web of Science ®Google Scholar
• Chen JR, Yen JH, Lin CC, et al. The effects of Chinese herbs on improving survival and inhibiting anti-ds DNA antibody production in lupus mice. Am J Chin Med. 1993;21(03n04): 257–262.
   PubMedGoogle Scholar